In Brief: SciGen, Institute of Drug Technology, Phosphagenics
Tuesday, 21 June, 2005
SciGen (ASX:SIE) has executed a commercialisation agreement with Rangs Pharmaceuticals for the commercialisation of insulin in Bangladesh. SciGen already has insulin commercialisation agreements in place for India, Pakistan and Sri Lanka.
The Institute of Drug Technology (ASX:IDT) will open and operate a second early phase clinical trial unit in Melbourne, in addition to its existing Adelaide based clinical unit CMAX. IDT anticipates the facility will be operational by August 2005.
A preclinical trial of Phosphagenics' (ASX:POH, AIM:PSG) drug delivery system TPM-01 has found successful delivery of the bio-active fragment of human parathyroid hormone through the skin. Parathyroid hormone is a naturally occurring polypeptide and can be used in the treatment of osteoporosis by daily injection. Phosphagenics has filed a new patent application to protect its discovery and now plans to conduct further trials using its drug delivery system for the delivery of insulin and other peptides.
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...
